Previous close | 1.8000 |
Open | 1.7900 |
Bid | 1.8100 x 1000 |
Ask | 1.8400 x 700 |
Day's range | 1.7800 - 1.8500 |
52-week range | 1.7000 - 27.0000 |
Volume | |
Avg. volume | 3,434,887 |
Market cap | 124.451M |
Beta (5Y monthly) | -0.68 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Significant Revenue Growth Amidst Strategic Shifts and Clinical Developments
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2024 Earnings Call Transcript May 9, 2024 Amylyx Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.75071 EPS, expectations were $0.24. AMLX isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. My name […]
Amylyx Pharmaceuticals (AMLX) delivered earnings and revenue surprises of -291.67% and 21.74%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?